For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Ligand Pharmaceuticals, Inc.

USPTO Granted Patents = 139

% Expired Patents = 15.1

CIPO Patents = 2

EPO Patents = 12

Trademarks = 4

Forward Citations = 1,569

Loading Chart...

Loading Chart...

212 inventors (with patents filed for the assignee):

Lin Zhi (76 out of 127 patents)

Todd Kevin Jones (27 out of 110 patents)

James Patrick Edwards (23 out of 165 patents)

4. Cornelis Arjan Van Oeveren (22 out of 22 patents)

5. Marcus F Boehm (18 out of 64 patents)

6. Richard Alan Heyman (16 out of 24 patents)

7. Yixing Shen (15 out of 15 patents)

8. Bijan Pedram (15 out of 18 patents)

9. Christopher Michael Tegley (15 out of 89 patents)

10. Lawrence G Hamann (12 out of 65 patents)

11. Jason Conrad Pickens (12 out of 15 patents)

12. Robert Higuchi (10 out of 21 patents)

13. David T Winn (10 out of 21 patents)

14. Luc J Farmer (9 out of 57 patents)

15. Sarah J West (9 out of 9 patents)

Core Competencies:

Anti-CTLA-4 Antibodies

Selective Androgen Receptor Modulators

Prodrug Compounds

Hematopoietic Growth Factor

Nitric Oxide Donor Structures

Glucagon Receptor Antagonists

Heterocycle Amines

Thrombopoietin Modulating Compounds

Retinoid X Receptor Modulators

Nucleotide Prodrug Compounds

Mineralocorticoid Receptor Modulators

Benzyloxy Phosph(on)ate Compounds

139 patents: Sort by Forward Citations

1. 12552820 - Benzyloxy phosph(on)ate compounds (2026-02-17),

2. 12503428 - Tunable nitric oxide-releasing macromolecules having multiple nitric oxide donor structures (2025-12-23),

3. 12492393 - ANTI-CD137 ANTIBODIES AND METHODS OF USE THEREOF (2025-12-09),

4. 12492257 - ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF (2025-12-09),

5. 12479913 - POLYNUCLEOTIDE ENCODING ANTI-TIGIT AND ANTI-CD96 ANTIBODIES (2025-11-25),

6. 12403087 - Topical antiviral compositions, delivery systems, and methods of using the same (2025-09-02),

7. 12319651 - Crystalline forms and methods of producing crystalline forms of a compound (2025-06-03),

8. 12208071 - Glucagon receptor antagonists (2025-01-28),

9. 11970482 - Acetal compounds and therapeutic uses thereof (2024-04-30),

10. 11858938 - Imidazo-fused heterocycles and uses thereof (2024-01-02),

11. 11773110 - Heterocycle amines and uses thereof (2023-10-03),

12. 11566041 - Nucleotide prodrug compounds (2023-01-31),

13. 11413274 - Methods and compositions associated with the granulocyte colony-stimulating factor receptor (2022-08-16),

14. 11358931 - Selective androgen receptor modulators (SARMs) and uses thereof (2022-06-14),

15. 11278559 - Prodrug compounds and their uses (2022-03-22),

Company Overview

Ligand Pharmaceuticals, Inc., based in San Diego, CA, specializes in the development of innovative pharmaceutical compounds. The company focuses on a diverse range of core technologies, including anti-CTLA-4 antibodies, selective androgen receptor modulators, and prodrug compounds. Ligand's research extends to hematopoietic growth factors, nitric oxide donor structures, glucagon receptor antagonists, heterocycle amines, and thrombopoietin modulating compounds, positioning it as a key player in advancing therapeutic solutions across various medical fields.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

139 Patents

#39 in San Diego, CA

#622 in California

#2,799 in US

#5,817 in the World

San Diego, CA, United States of America

Ligand Pharmaceuticals, Inc.

Forward Citations = 1,569

212 inventors:

Lin Zhi (76 out of 127 patents)

Todd Kevin Jones (27 out of 110 patents)

James Patrick Edwards (23 out of 165 patents)

4. Cornelis Arjan Van Oeveren (22 out of 22 patents)

5. Marcus F Boehm (18 out of 64 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ligand Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/ligand-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…